Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 26, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on October 25, 2005, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 1,382 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on October 26, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held in the GSK Trust in the same capacity as other employees. The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares transferred (1,382) and the date of transfer (October 25, 2005).
- Confirm the specific employee share option plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Identify the directors with interests in the GSK Trust: Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop.
- Note that this filing does not contain financial results; refer to Form 20-F for comprehensive financial data.